• 제목/요약/키워드: 바렛식도

검색결과 2건 처리시간 0.016초

바렛 식도에 발생한 식도 선암종의 수술적 치료 - 1예 보고 - (Surgical Treatment of Esophageal Adenocarcinoma in Barrett's Esophagus - A case report -)

  • 정원상;강정호;송영주;김영학;김혁
    • Journal of Chest Surgery
    • /
    • 제41권6호
    • /
    • pp.787-790
    • /
    • 2008
  • 바렛식도는 식도선암의 전구 병변으로 알려져 있으나, 우리나라에서는 보고된 예가 극히 드물다. 본 원에서는 81세 남자에서 식도선암 진단 하에, 부분식도절제술 및 식도-위 단단문합술을 시행하였다. 절제된 조직의 병리검사에서 식도 선암종 주위의 배상세포를 동반한 장상피화생을 관찰할 수 있었다. 이에 문헌고찰과 함께 보고하는 바이다.

바렛식도의 화학예방 (Chemoprevention of Barrett's Esophagus)

  • 송경호
    • Journal of Digestive Cancer Research
    • /
    • 제11권1호
    • /
    • pp.9-14
    • /
    • 2023
  • The prevalence of Barrett's esophagus is increasing in South Korea. Several strategies have been tried to prevent its progression to esophageal adenocarcinoma. It is questionable whether the strategies being tried in the West can be applied adequately in South Korea. However, despite the incidence of esophageal adenocarcinoma in the West, which is considerably higher than that in South Korea, the incidence of high-grade dysplasia/esophageal adenocarcinoma in population-based studies is as low as 0.23%/person-year. Therefore, in Korea, where the prevalence is lower than that, it is necessary to select high-risk groups more carefully for chemoprevention. The age of onset of gastroesophageal reflux disease-like symptoms at least once a week is related to the high-risk group rather than the presence or absence of chronic gastroesophageal reflux symptoms. The risk factors for esophageal adenocarcinoma include the patient's sex, age, smoking habit, and obesity. Proton pump inhibitors have a better preventive effect against esophageal adenocarcinoma compared to H2-receptor blockers, but their application to patients in Korea is limited due to the high number of individuals in need of treatment. Therefore, while considering the risk factors for the progression of esophageal adenocarcinoma, the administration of proton pump inhibitors should be considered for gastroesophageal reflux disease.